Print 22 comment(s) - last by Totally.. on Sep 1 at 4:54 AM

  (Source: YouTube)
Amid efficacy questions, a Japanese antiviral drug is also being evaluated to combat the deadly disease

The World Health Organization (WHO), the health department of the United Nations (UN), revealed on Friday that the Ebola virus (EBOV) epidemic that's gripped central Africa has now claimed over 1,400 lives.  Adding to the bad news, supplies of the experimental drug ZMapp have reportedly been exhausted and a recent death of a ZMapp-treated doctor is increasing questions of the drug's efficacy, as health workers in Africa desperately search for a way to treat -- or at least stop the spread of -- the deadly virus. 

I. ZMapp -- an Exotic Treatment Option

ZMapp is a monoclonal antibody produced in plants, and then humanized.  Antibodies are large Y-shapped proteins that the human body uses to tag "antigens" surface chemicals on hostile invaders such as viruses and bacteria.  More specifically, in this case the antibodies are thought to tag strains of the Ebola family of viruses (EBOVs), including the most prevalent and deadly titular strain, the Ebola virus (EBOV) (aka Zaire virus, or Zaire ebolavirus).

Ebola colorized
The Ebola virus is cutting a wake of destruction across Central Africa. [Image Source: AP]
The ZMapp effort was formed by the merger of two attempts to produce monoclonal antibody serums via genetically modified organism (GMOs).  The first serum was MB-003, formulated by San Diego, Calif.-based Mapp Biopharmaceutical, Inc. and its commerical sister-firm LeafBio.  Both Mapp and Leafbio were funded [PDF] in part by grants from the U.S. Army Medical Research Institute of Infectious Diseases (USAMRID).  The second serum was ZMAb, made by Toronto-based Defyrus Inc., a startup funded in part by grants from a Public Health Agency of Canada (PHAC) grant.

Both Defyrus and Mapp/LeafBio are tiny, very young firms; Defyrus was found in 2008, Mapp in 2003.  Defyrus has six employees, Mapp has nine.  Both companies look to use purified antibodies from GMOs to try to boost a patients' defense against disease which currently have no cure.  Because of this, both companies fall under the so-called "biodefense" category as they could provide a novel tool to combat rare deadly diseases -- a highly coveted weaponizable class of pathogens.

The ZMapp cocktail is produced by infecting Nicotiana benthamiana, a close relative of cigarette tobacco, with a virus similar to the target viral agent.  The tobacco plants are grown at the U.S. and Canadian companies' German partner firm, Icon Genetics.  Leaves are grown in small batches at Icon Genetic's greenhouse.  Genes are introduced into the plants via recombinant bacteria administered by eyedroppers.

ZMapp nicotine leaves
Leaves are picked at a Icon Genetics greenhouse in Germany and readied for extraction.
[Image Source: Reuters]

The crop responds to the infection by producing antibodies.  After the harvest, workers much grind the leaves and carry out a set of hand extractions and purifications.

Via this costly, slow process a batch of serum is made.  The antibodies are "humanized" either using recombinant DNA in the plant or via scaffold or rodent reporcessing -- processes that make these immune proteins compatible with the human body, despite coming from a highly different source organism.

Hand extraction
Defyrus and Mapp/LeafBio must painstakingly extract and mix the proteins for each batch of ZMapp by hand.
[Image Source: Reuters]

Humanized monoclonal antibodies are being considered for novel forms of cancer treatment, as well as for combatting rare and understudied diseases.  The fundamental idea in both cases is to get nature to do medical researchers' dirty work at a much faster speed.  The downside is that these treatments get very expensive as the process is very new.  Purification and humanification technologies are far from achieving the levels needed to achieve the production associated with common antibiotics and vaccines.  And many of the formulations -- including ZMapp -- have not gone through clinical trials, and at this point can be considered at best educated guesses.

II. Great Expectations

At first it perhaps appeared to the overly hopeful observer that ZMapp might be a magic bullet for the EBOV.  After Mapp and Defyrus received a rare exemption from the U.S. Food and Drug Administration (FDA) allowing experimental treatment of patients with a drug that has yet to undergo clinical trials, the ZMapp formula was used to treat two Americans.  
The lucky potentially lucky recipients of the expensive experimental cocktail were Kent Brantly, a 33-year-old doctor, and Nancy Writebol, a 59-year-old aid worker.  Both the patients became infected while trying to assist in combating the current EBOV outbreak in Central Africa.

Both American patients treated with ZMapp recovered fully. [Image Source: Bloomberg]

Treated at Emory University Hospital near Atlanta, Georgia, both patients made remarkable recoveries.  Closely monitored by teams of doctors and provided an ample supply of sterile fluids to keep them hydrated, both of these ZMapp-treated patients made full recoveries. Recently, after a quarantine they were allowed to go home to family members in the U.S. after being deemed no longer contagious.  Dr. Brantly cheered that his recovery with the help of ZMapp was "miraculous."

Cheered by the results, further purchases of ZMapp were made to treat an infected Spanish missionary and African doctors.  The serum was also given to 
three African doctors treating patients in Liberia who had become infected with EBOV.  After receiving doses of ZMapp all three doctors subsequently showed signs of a "remarkable" recovery, according to local officials.

But the optimism was dampered somewhat when Rev. Miguel Pajares, a 75-year-old missionary, died despite receiving treatment with ZMapp.  Rev. Pajares was treated at the state of the art Carlos III Hospital in Madrid, Spain, but neither the cutting edge medical center nor the ZMapp was able to save his life.

More bad news arrived this week when Liberia's Dr. Abraham Borbor -- one of the African doctors who received ZMapp -- took a turn for the worse and died, after appearing poised to make a full recovery.  News of the death was shared to various outlets by Liberian Information Minister Lewis Brown.  The loss of Dr. Borbor was a major blow as he was the Deputy Chief Medical Doctor of the leading medical institution in hardest hit African nation, Liberia.  Dr. Borbor's age was not widely reported, but he appears to be middle-aged.
Dr. Borbor
Dr. Abraham Borbor, a top medical doctor in Liberia, died this week, despite being one of only three Africans to receive treatment with the expensive drug ZMapp. [Image Source: Dailly Mail]

The latest development calls into question to some extent the efficacy of ZMapp, as thus far 2 patients treated with it have died, while two have made full recoveries.  Further complicating the issue is that supplies of ZMapp have run out, so there can be no more additional tests for now.  Mapp/LeafBio and Defyrus are working to prepare more doses, but they may not be ready until a few months from now, given the lengthy grow time need to make small batches of the treatment.

Some will surely point to potential differences the condition and treatment of patients who were given ZMapp and died versus those who lived.  Both of the patients who made full recoveries were younger than 65 and were treated at modern medical institutions.  Of those who died, the Liberian doctor was treated at a top regional facility, but without some of the advanced amenities of a European or Amerian hospital.  The Spanish priest's age, meanwhile, is being attributed as a factor in that case for the lack of success.

III. Now It's Toyama's Turn

Greater mortality rates for the infection are estimated to be around 55 percent, according to BBC News.  And that brings to bear the elephant in the room. Other factors aside, the survival rate for ZMapp treated patients isn't significantly higher.

The scant supply of ZMapp has been exhausted without conclusive results. [Image Source: Getty Images]

At the end of the day, though, we're back to where we started.  ZMapp may indeed be useful in combatting the disease, but it remains highly expensive and slow to produce.  Worse, critics and proponents at best have educated speculation and anecdotal cases studies to rely upon when trying to determine its efficacy.  ZMapp may "work" to some extent; or it may have little impact on the course of the disease versus other factors.  At this point there simply isn't enough evidence to determine which is the case.

But if ZMapp can't stop Ebola, what can?  The answer may lie in other experimental drugs, such as T-705, an antiviral drug marketed under the name Avigan.  This new antiviral is produced by Japan's Toyama Chemical Comp., Ltd., which recently became a subsidiary of Fujifilm Holdings Corp. (TYO:4901).  Avigan has been through limited clinical trials with other viruses.  It is currently approved of to treat influenza in Japan.

Avigan action
Avigan, an inhibitor of viral RNA polymerases, is being tried as an alternative to ZMapp.
[Image Source: Fujifilm]

No one knows if it will be able to similarly slow EBOVs, but Japan has already cleared red tape to allow it to ship worldwide -- with or without WHO approval.  Avigan is currently being tested on William Pooley, a 29-year-old British volunteer, who returned home after contracting EBOV as a relief worker.  He's being treated in isolation at a London, UK hospital.

Should Avigan pan out, the big upside is that unlike ZMapp, it could potentially be produced at much higher volume and far more quickly.  Indeed, Fujifilm and Toyama Chemical sound eager to do so.  But care must be taken as thus far other less exotic antivirals have had little success at combatting EBOV.  The worst case scenario would be for afflicted nations to purchase large stocks of the antiviral, only to find in an inaffective treatment.

Meanwhile the disease marches on, unchecked in the worst-hit nations of Liberia and Sierra Leone.  The latest statistics from the WHO lists 2,615 infections and 1,427 deaths for the latest outbreak -- a infection count higher than the past 20 EBOV outbreaks combined.
Ebola Spread
The death toll from the epidemic has topped 1,400. [Image Source: CDC]

The good news is that Nigeria -- Africa's most populous nation -- has thus far managed to constrain EBOV disease occurences to a dozen or so cases.  Of the five deaths in Nigeria, all have been related to those who came in contact with an American-born citizen of Liberia who traveled to Nigeria after becoming infected with EBOV in his home country.

But in Liberia, particularly, the situation remains grim.

Sources: WHO, BBC News

Comments     Threshold

This article is over a month old, voting and posting comments is disabled

What will it take to stop the spread of ebola?
By Bill S. on 8/26/2014 8:04:00 AM , Rating: 3
Remember the movie "Outbreak"?

Just keep Dustin Hoffman away from the area when you go to firebomb/nuke it, please?

By retrospooty on 8/26/2014 11:07:06 AM , Rating: 3
Seeing as how its not airborne and spread only by bodily fluid, its not going to be a mass outbreak like bad flu or Outbreak. You have to be sneezed on, or touch someone with it. You cant catch it by being in the same room.

RE: What will it take to stop the spread of ebola?
By Ammohunt on 8/26/14, Rating: 0
RE: What will it take to stop the spread of ebola?
By carigis on 8/26/2014 4:01:04 PM , Rating: 2
its been stable since 1976.. so not likely to mutate.. naturally at least into airborn.

By Ammohunt on 8/29/2014 2:43:36 PM , Rating: 2
395 mutation in the last 10 years 50 in the first month of the outbreak.

By Reclaimer77 on 8/26/2014 4:30:02 PM , Rating: 2
Not yet....


By Ammohunt on 8/27/2014 5:40:25 PM , Rating: 2
The renown virologist Dr. Reclaimer77 has spoketh! Silly me to think viruses in the wild mutate.

By LocalBarista on 8/30/2014 12:59:53 PM , Rating: 2
You can't claim that, anything alive has a factor of plasticity. As long as that exists it can mutate. The problem is that the rate of mutation is directly tied to population and environment, since the outbreak of the virus, the mutation rate has spiked dramatically. IIRC, it has mutated about 50 times or so, whereas before it was stable.

By Sunrise089 on 8/27/2014 11:30:01 AM , Rating: 3
[Very much not trying to be trollish here]

Might it be something akin to airborne? Obviously it's not spreading like the flu, but it also seems to be infecting medical professionals who should know better than to get patient fluids on their unprotected skin or into their body. I'm certainly not a medical professional, but I find it challenging to accept, say, an AIDS-like difficulty in being transmitted with the number of highly credentialed doctors who have come down with the disease.

RE: What will it take to stop the spread of ebola?
By Mitch101 on 8/26/2014 11:19:29 AM , Rating: 3
Chuck Norris
Bruce Willis
just sayin.

By Totally on 9/1/2014 4:54:59 AM , Rating: 2
That would only result in the creation of the Chucknola Virus. A mutation cause by the Ebola virus being infected with Chuck Norris which would lead to the demise of all known life and the possible demise of Chuck Norris. If nothing is alive to confirm the existence of Chuck Norris does he exist?

By Grimer21 on 8/26/2014 12:10:27 PM , Rating: 2
Anyone have any ballpark for how much a full treatment of ZMapp costs USD? I'm just curious.

RE: Cost?
By tayb on 8/26/2014 3:50:42 PM , Rating: 2
It's an experimental drug and was seemingly gifted under compassionate care. There is likely no way to purchase the drug at this time and as such no purchase price.

RE: Cost?
By ImmortalSamurai on 8/26/2014 4:12:30 PM , Rating: 3
We don't know. Samaritan's Purse covered the cost of Brantly and Writebol's evacuations but did not pay for the drug, according to a spokesman.
When a patient gets an experimental drug, the drug company can donate the product under compassionate use. Mapp Biopharmaceutical Inc. might have done that in this case.
Health insurance companies typically do not pick up the tab for treatments that have not been approved by the FDA. But they usually would cover the cost of any doctor fees associated with giving the drug and any costs associated with monitoring how the drug is working.

RE: Cost?
By inperfectdarkness on 8/27/2014 4:05:17 AM , Rating: 2
Probably about the same as the Magic Johnson AIDS cure.

And if you think that's a politically incorrect joke, then you probably don't watch South Park...

Author misunderstands ZMapp
By sealiz on 8/26/2014 5:48:52 AM , Rating: 4
The author seems to misunderstand ZMapp. In preclinical trials, its primary use was preventative. It showed a little promise for post infection and that's why it was given as "compassionate treatment".

He also makes it sound like the production is all done by hand. The vaccine was produced at Kentucky Bioprossessing, which has larger scale production facilities than an R&D setup. Anyone with knowledge of the biotech sector would realize that for the quantities needed the production would not be done manually.

Furthermore, the start up for production of any new therapeutic takes a long time. Scale up of any process means new factors must be considered.

RE: Author misunderstands ZMapp
By Bubbacub on 8/27/2014 9:25:40 AM , Rating: 4
Why let a completely inadequate understanding of a subject matter stop you from making a fool of yourself on the internet?

maybe it doesn't work on blacks?
By carigis on 8/26/2014 3:59:43 PM , Rating: 2
hats a shame.. was looking good. maybe it just doesnt work on africans which would be a real tragedy.. given where the disease is located..but not unprecedented .. beta blockers for instance don't work well on black people but work fine on Caucasians.

RE: maybe it doesn't work on blacks?
By kyuuketsuki on 8/27/2014 12:01:04 AM , Rating: 1
But the optimism was dampered somewhat when Rev. Miguel Pajares, a 75-year-old missionary, died despite receiving treatment with ZMapp. Rev. Pajares was treated at the state of the art Carlos III Hospital in Madrid, Spain, but neither the cutting edge medical center nor the ZMapp was able to save his life.

Considering Rev. Parajes was Spanish and not likely of African-heritage, I don't think it's a case of it not working on "blacks".

By Brockway on 8/28/2014 9:16:29 AM , Rating: 2
Are we looking at the same picture? Ever heard of the Moors? Didn't realize nationality=race now.

For those in denial
By Ammohunt on 8/28/2014 3:39:18 PM , Rating: 2
I Vant to...
By rbuszka on 8/28/2014 5:04:19 PM , Rating: 2
I wonder if the Ebola antibodies that are taken from the tobacco plant and somehow "humanized" would have the effect of giving the body's own immune system time to develop antibodies of its own against the virus, and then whether a blood transfusion from any known cured patient to an infected patient could provide the needed antibodies in the bloodstream to fight the virus off.

Antibodies are chemical markers that identify a virus as a disease agent for white blood cells to attack, so the only question is how many of these markers need to be present to reverse an early-stage but confirmed Ebola infection, and whether the necessary number of antibodies exist in just a small amount of blood from a treated and "cured" person.

I'm by no means a medical doctor or analyst, but I just raise these possibilities out of interest. If the transfusion method of treatment is possible, then the blood of the two cured patients (with antibodies) could become one of the most precious commodities on the planet in a short span of time. No need for FDA approval of a drug because no drug is involved.

"The Space Elevator will be built about 50 years after everyone stops laughing" -- Sir Arthur C. Clarke

Copyright 2016 DailyTech LLC. - RSS Feed | Advertise | About Us | Ethics | FAQ | Terms, Conditions & Privacy Information | Kristopher Kubicki